References

Barrett KOxford: Oxford University Press; 2010

Dikken C2008

Crawford SM A/H1N1 Flu Pandemic: Managing Neutropenic Sepsis. BMJ. 2009; 339:(768)

Incidence, mortality and economic burden of sepsis. 2007. http//tinyurl.com/644bskv

London: Department of Health; 2000

Department of Health. 2004. http//tinyurl.com/6f6w7y5

Dellinger RP, Levy MM, Carlet JM Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Medicine. 2008; 36:(1)296-327

Demetri GD, Von Mehren M, Blanke CD Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors. NEJM. 2002; 347:(7)472-80

Goldman B Multidrug resistance: Can new drugs help chemotherapy score against cancer. J Natl Cancer Inst. 2003; 95:(4)255-7

Kindt TJ, Goldsby RA, Osborne BANew York: 6th Edn. W.H. Freeman and Company; 2007

Kitchen G, Griffin J, Arif SEdinburgh: 3rd Edn. Mosby Elsevier; 2007

Levy MM, Fink MP, Marshall JC 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Medicine. 2003; 29:(4)530-8

Llewellyn M, Cohen JBerlin: 2nd Edn. Springer; 2007

National Confidential Enquiry of Patient Outcome and Death (NCEPOD). 2008. http//tinyurl.com/ychptvo

National Chemotherapy Advisory Group (NCAG) Report. 2009. http//tinyurl.com/2ztgk9

Morgan G Chemotherapy and the Cell Cycle. CancerNursing Practice. 2003; 2:(1)27-30

Penack O, Beinert T, Buchheidt D Management of Sepsis in neutropenia: guidelines of the infectious diseases working party. Annals of Haematology. 2006; 85:(7)424-33

Poeze M, Ramsay G, Gerlag H An international sepsis survey: a study of doctors' knowledge and perception of sepsis. Critical Care. 2004; 8:(6)R409-R413 http//tinyurl.com/49nz6eu

Reigle BS, Dienger M Sepsis and treatment-induced immunosuppression in the patient with cancer. Critical Care Nursing Clinics of North America. 2003; 15:(1)109-18

Robson W, Beavis S, Spittle N An audit of ward nurses' knowledge of sepsis. Nursing in Critical Care. 2006; 12:(2)86-92

Robson W, Daniels R The sepsis six: helping patients survive sepsis. British Journal of Nursing. 2008; 17:(1)16-21

Strelkauskas A, Strelkauskas J, Moszyk-Strelkauskas DNew York: Garland Science; 2010

Surviving Sepsis Campaign. 2007. http//www.tinyurl.com/66hsjhb

Townsend S, Dellinger RP, Levy MMIL: The Society of Critical Care Medicine, the European Society of Intensive Care Medicine and the International Sepsis Forum, Des Plaines; 2005

Yarbo CH, Frogge M H, Goodman M, 6th Edition. London: Jones and Bartlett Publishers; 2005

Neutropenic sepsis: preventing an avoidable tragedy

04 March 2011
Volume 3 · Issue 3

Abstract

Neutropenic sepsis is a life-threatening side-effect of chemotherapy—patients are still dying from this complication of treatment, and these deaths are largely preventable. The purpose of this article is to raise awareness of the condition, its severity and the importance of timely responses to it. The main issue for prehospital clinicians is that symptoms of neutropenic sepsis, especially in the early stages, are so vague that they are easily misinterpreted or dismissed as opposed to being indicative of a time-critical patient. The patient's history is of paramount importance in identifying patients in the community that are vulnerable to the condition—those recovering from chemotherapy. These patients are highly prone to infection and are temporarily immune compromized due to the medications that they have been prescribed. They are incapable of mounting a response to infection and infective agents can overwhelm them rapidly. It is imperative in this patient group to have a high degree of suspicion about ‘simple’ assessment findings and non-specific symptoms as these can progress very quickly to haemodynamic collapse and death. Timely hospital-directed antibiotic therapy and support can prevent this possible tragedy.

Over the last decade, major improvements have been made in the treatment of cancer. The NHS Cancer Plan (Department of Health (DH), 2000) has assisted this by providing structure and funding to improve cancer services throughout England.

Chemotherapy, the use of cytotoxic medications, is one of the essential treatments available for cancer. There has been an exponential increase in the use of chemotherapies for a wide range of tumour sites—in fact, the list of chemotherapy resistant cancers is rapidly diminishing due to the development of new and effective drug therapies (Demetri et al, 2002; Goldman, 2003).

Over the years, chemotherapy treatments for advanced metastatic cancer have also improved which is resulting in patients receiving an increasing number of courses of treatment. Adjuvant chemotherapy has become more aggressive, with dose escalation and accelerated regimes being offered in trial settings.

Subscribe to get full access to the Journal of Paramedic Practice

Thank you for visiting the Journal of Paramedic Practice and reading our archive of expert clinical content. If you would like to read more from the only journal dedicated to those working in emergency care, you can start your subscription today for just £48.

What's included

  • CPD Focus

  • Develop your career

  • Stay informed